Abstracts A175 ics. SAS version 9.2 was used for analyses of data. Descriptive statistics were obtained by using survey frequency procedures that accounted for survey design and weighting. Weighted analyses were performed using survey logistic procedure controlling for interactions amongst the independent variables. RESULTS : During the 2 year period  from 2005 and 2006, 3500 patients representing 12,769,828 CAD patients were  identified. A total of 340 CAD patients representing 1,229,496 patients underwent  CT scan procedure. Observations with missing data were deleted as it constituted less than 1% of the total identified population. Following variables were found significantly associated with probability of getting a CT scan: Painlevel, EKG use, Physician seen, Physician assistant seen, Race/ethnicity and Mode of arrival. These variables do not act in isolation and interactions between them were considered in the analyses CONCLUSIONS: The use of CT scan as a diagnostic tool in CAD patients admitted in ED depends on a multitude of interdependent factors such as patient characteristics defined by painlevel, race/ethnicity, provider characteristics or the type of provider seen and type of health service utilized such as ambulance and concurrent EKG use. OBJECTIVES: Better selection of ischemic stroke patients for intravenous recombinant tissue plasminogen activator (IV tPA) treatment based on the penumbral hypothesis as seen through magnetic resonance imaging (MRI) by may improve clinical outcomes. However given the limited availability of MRIs in hospitals, MRI-based methods may not be feasible. We examined the cost-effectiveness of adding perfusion imaging with computed tomography (CTP) to usual computed tomography (CT)based methods to examine presence and extent of penumbra such that patients can be identified for IV tPA treatment. METHODS: A decision-analytic model was developed to estimate costs and outcomes associated with selecting patients for IV tPA treatment via CTP compared to current usual care of selection based on CT scan and patient history from a hospital perspective. The patient population was similar to that observed in the IV tPA clinical trials included in a recent meta-analysis. Clinical data was derived from published clinical trials. Costs were obtained from standard US costing sources and utilities were obtained from published literature. All costs are presented in 2009 US dollars. Outcomes included cost per life-year saved and cost per quality-adjusted life-year (QALY) gained. Sensitivity analyses were conducted. RESULTS: From the hospital perspective, the addition of penumbral-based CTP selection improved favorable outcome (modified Rankin Scale ≤1) by 0.59% and reduced cost by $42 compared with usual CT-based selection at hospital discharge. Life years and QALYs improved which resulted in the addition of penumbral-based CTP selection in being cost-savings to hospitals. Multivariate sensitivity analysis predicted cost-effectiveness (≤$50,000 per QALY) in 89.2% of simulation runs. CONCLU-SIONS: Given costs and the limited availability of MRI, penumbral-based CTP after routine CT is a cost effective alternative for hospitals in selecting ischemic stroke patients for IV tPA treatment.
1
University of Maryland School of Pharmacy, Baltimore, MD, USA, 2 University of Maryland, Baltimore, Baltimore, MD, USA OBJECTIVES: The recent re-label of clopidogrel to include information on CYP2C19 genotype and the approval of a second-generation antiplatelet medication, prasugrel, could greatly impact the way antiplatelet therapy is prescribed. This study assesses the cost-effectiveness of genotyping patients to guide selection of antiplatelet therapy with clopidogrel or prasugrel. METHODS: A decision tree was created using prevalence of CYP2C19 metabolism status, cardiovascular events, and bleeding events and costs of events as reported in the literature and publically available FDA advisory committee documents. In the genotype arm, an individual's metabolic status determined medication selection. Effect was defined as the cost per event avoided. Scenario analyses that were conducted to determine the robustness of the model included scenario A: clopidogrel use without genotyping and scenario B: prasugrel use without genotyping. Number needed to genotype to avoid one cardiovascular or bleeding event from occurring was also determined. RESULTS: The probability of being an ultra-rapid or extensive metabolizer of CYP2C19 was 73% and the probability of being an intermediate or poor metabolizer was 27%. For the no-genotype arm, the estimated proportions of medication selection used were 70% to receive clopidogrel and 30% to receive prasugrel. The model favored the intervention of genotyping patients to determine antiplatelet therapy (ICER: −$20,049). Both scenario analyses exhibited a dominant strategy of genotyping patients (ICERA: −$21,833 and ICERB: −$15,918). Number needed to genotype to avoid one bleeding or cardiovascular event was 26. CONCLUSIONS: The cost-effectiveness analysis suggests it is more effective and less costly to genotype patients prior to selecting clopidogrel or prasugrel for the patient's antiplatelet therapy.
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READMISSIONS AFTER UNAUTHORIZED DISCHARGES IN THE CARDIOVASCULAR SETTING
Onukwugha E, Mullins CD 1 , Loh FE 2 , Saunders E 3 , Shaya FT 1 , Weir MR 3 1 University of Maryland School of Pharmacy, Baltimore, MD, USA, 2 University of Maryland, School of Pharmacy, Baltimore, MD, USA, 3 University of Maryland School of Medicine, Baltimore, MD, USA OBJECTIVES: Patients who self-discharge against medical advice (AMA) may be at higher risk for a hospital readmission if the unauthorized discharge was premature. The study objective is to examine the relationship between discharges AMA and cardiovascular disease (CVD) hospital readmissions while addressing bias due to potential confounding, selection, and hospital-level clustering. METHODS: This cross-sectional study uses confidential inpatient hospital discharge data covering the years 2000 to 2005. The outcome variables captured readmissions for a CVD-related condition following an index CVD-related admission. The covariate of interest was an indicator variable for a discharge AMA in the index hospitalization. The relationship between discharges AMA and 7-day, 31-day, 180-day, and 365-day hospital readmissions was examined using generalized linear models with adjustments for clustering and selection bias. RESULTS: The sample included 443,088 patients, of which 22,757 (5.1%) were readmitted to the same hospital. Approximately 1% of the patients who were readmitted in the hospital during the study period left AMA on the index admission while 0.89% of those who were not readmitted left AMA (p = 0.047). The odds of a CVD-related readmission within 7 days, 31 days, 180 days and 365 days were 145% (p < 0.001), 55% (p < 0.001), 26% (p < 0.001) and 15% (p = 0.0011) higher for patients discharged AMA on index admission compared to those who were discharged formally. Results are robust to corrections for observable selection bias (via propensity score analysis) and hospital-level clustering. CONCLU-SIONS: A self-discharge AMA among patients admitted for CVD is predictive of CVD-related readmissions and the strength of association increases as the time between admissions decreases.
PCV135 TREATMENT PATTERNS IN ATRIAL FIBRILLATION: AGENTS USED IN CURRENT PATIENT MANAGEMENT
Emons MF 1 , Lin J 2 , Yu HT 1 1 Cerner LifeSciences, Beverly Hills, CA, USA, 2 Sanofi-Aventis, Bridgewater, NJ, USA OBJECTIVES: Future refinement of pharmacotherapy of atrial fibrillation/atrial flutter (AF) requires a detailed understanding of how treatments are currently employed in clinical practice. METHODS: In this retrospective cohort study, we used the US MarketScan ® database to identify patients ≥18 years with AF (≥1 AF inpatient or ≥2 outpatient AF claims) and ≥18 months' continuous enrollment data between Jan 2003 and Sept 2007. The first qualifying AF diagnosis following 12 months' enrollment was designated the index diagnosis. AF was classified as newly-diagnosed (ND) or preexisting (PRE), based on treatment history in the pre-index period. RESULTS: Of 184,155 identified patients (mean age 73 years, 55% men), 64,669 had ND and 119,486 had PRE AF. Non-pharmacotherapy for AF was undertaken in 11% of patients with ND vs 6% of patients with PRE disease, most commonly cardioversion (9% vs. 4% of patients, respectively). Across both patient groups, 30% received no drug therapy within 30 days of initial AF diagnosis (initial treatment), 17% received antiarrhythmics (rhythm-control agents), 51% rate-control agents, 40% anticoagulants, and 5% antiplatelets (aspirin use was not captured). Median duration of uninterrupted initial therapy was 210 days for antiarrhythmics and antiplatelets, 228 days for anticoagulants and 420 days for rate-control agents. Over the entire post-index follow-up period (mean 20 months), ND and PRE AF patients received antiarrhythmics (27% vs 28%), rate-control agents (77% vs 76%), anticoagulants (54% vs. 66%) and antiplatelets (14% vs. 10%). Overall, the most commonly used drugs were amiodarone (15%), β-blockers (56%), calcium channel blockers (23%), cardiac glycosides (35%), warfarin (61%) and clopidogrel (11%). CONCLUSIONS: Non-pharmacological interventions for AF were relatively uncommon. Almost one-third of AF patients in our study remained untreated for the first 30 days after diagnosis, which may represent under-treatment. Rate-control agents and anticoagulants were used more frequently than antiarrhythmics and antiplatelets for treatment of AF.
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PRIORITY-SETTING FOR COMPARATIVE EFFECTIVENESS RESEARCH
Seidenfeld JD, Montgomery RW, Sonnad S Center for Medical Technology Policy, Baltimore, MD, USA OBJECTIVES: Coincident with the increasing focus on comparative effectiveness research (CER), a number of organizations have begun to engage in prioritizing topics for CER. This paper presents the priority-setting process developed by the Center for Medical Technology Policy (CMTP) and its application to the selection of cardiac technologies. METHODS: We reviewed criteria and processes used by other organizations. We then developed a multi-stage process including, 1) horizon scanning; 2) topic nomination; 3) expert solicitation; 4) topic review and selection; 5) criteria application and discussion by a expert workgroup, and 6) final ranking of topics for varied research projects. After internally refining a broad list to the top ten technologies, we convened an expert workgroup charged with ranking these top technologies using prospectively developed criteria. Experts were provided with a list of criteria and briefs summarizing clinical, economic, and ethical aspects of each technology. RESULTS: Topic nomination produced an initial list of approximately 40 technologies, which were narrowed to the top ten based on suitability for CMTP's coverage with evidence development (CED) initiatives and guidelines for designing CER studies projects. The expert working group ranked technologies according to suitability for both CED and the guideline projects. The top 3 technologies that emerged for CED were 1) pharmacogenetic guidance of warfarin dosing; 2) catheter ablation for atrial fibrillation; and 3) percutaneous aortic valve replacement. For the guidelines, the ranking was 1) C-reactive protein tests; 2) genetic testing for heart disease; and 3) bioabsorbable stents. CONCLUSIONS: A prospectively developed multi-step process focusing on technologies within a disease area may improve the process of prioritizing technologies for CER, offering more direct guidance to researchers and policy makers. Notably, CMTP is initiating a CED project and the advisory workgroup selected the warfarin dosing topic, indicating the success of the process in choosing a relevant technology.
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ANALYSIS OF HEALTH CARE OUTCOME FOR CONGESTIVE HEART FAILURE (CHF) PATIENTS Ugiliweneza B
University of Louisville, Louisville, KY, USA OBJECTIVES: To analyze the difference of in-stay hospitalization frequency between Congestive Heart Failure (CHF) patients who are on the recommended medication and those who are not. METHODS: We use the inpatient, outpatient and medication files from the Thomson Reuters MarketScan data records of 2000 and 2001. First, we extract patients with CHF from the inpatient and outpatient files using ICD9 codes. Next, we extract these patients from the medication files. Depending on the NYHA classification, there is a recommended combination of medication a CHF patient should have. We use these medications to divide the patients into two groups. Then, we analyze the data using logistic regression, kernel density estimation and ANOVA. The preprocessing and the statistical analysis are done using SAS software. RESULTS: The analysis yields a statistically noteworthy difference in proportions of number of in-stay hospitalizations between people on the recommended treatment and those who are not. Also, there is significant difference in length of stay for the two groups. CONCLUSIONS: Being on the recommended combination of medication has a significant impact on the health care outcome for CHF patients.
PCV138 ASSESSING THE IMPACT OF AN EMPLOYER SPONSORED COMMUNITY PHARMACY BASED MTM PROGRAM ON CLINICAL OUTCOMES FOR PATIENTS WITH DIABETES AND HYPERTENSION
Pinto S 1 , Ferrell M 1 , Partha G 1 , Bechtol R 2 , Coehrs B 3 , Riepenhoff C 3 1 University of Toledo, Toledo, OH, USA, 2 The University of Toledo, College of Pharmacy, Toledo, OH, USA, 3 Pharmacy Counter, Toledo, OH, USA OBJECTIVES: To examine the effect of an employer-sponsored, pharmacist-provided medication therapy management program (MTM) on clinical outcomes and process measures in patients with diabetes and hypertension METHODS: A prospective, intent-to-treat, pre-post longitudinal study. Patients were Lucas County employees and dependents with diabetes, hypertension, or both. The MTM services were provided by independent pharmacists in Northwest Ohio at seven sites. ADA and JNC-VII guidelines were used to design interventions and set patient goals. Data was analyzed using SPSS v17.0 for three groups-hypertension only, diabetics, and hypertensive diabetics. Wilcoxon signed-rank test was used to compare 2 time points and the Friedman test was used to compare readings at baseline, 6,12,and 18 months. RESULTS: Five hundred eighty six patients enrolled at baseline. The Hypertension only group mean systolic blood pressure (SBP) improved from 135.37 ± 18.85 to 130.33 ± 18.35 (p = 0.057). Diastolic blood pressure (DBP) improved from 81.71 ± 10.70 to 80.35 ± 11.12 (p = .386). Uncontrolled hypertensive patient's SBP mean improved from 153.03 ± 12.37 to 138.91 ± 19.74 (p < 0.01). DBP improved from 97.07 ± 5.71 to 85.6 ± 13.20 (p < 0.05). For hypertensive diabetic patients SBP improved from 134.59 ± 18.99 to 128.35 ± 18.55 (p = 0.20). DBP improved from 81.52 ± 11.25 to 79.52 ± 12.08 (p = 0.75). Uncontrolled diabetic hypertensive patients SBP mean improved from 145.96 ± 13.83 to 135.29 ± 17.62 (p < 0.05). DBP improved from 87.51 ± 6.54 to 82.71 ± 11.92 (p = 0.439). For uncontrolled diabetic patients A1c improved significantly from 8.02 ± 1.31 to 7.41 ± 0.99 (p < 0.001). Patients with controlled A1c at baseline were able to maintain control for the 18 months of participation in the study. Upon being advised by their pharmacists more patients visited their dentist, podiatrist, and ophthalmologist. CONCLUSIONS: Pharmacists were able to help patients maintain A1c and BP goals thereby preventing future complications and costs to the employer.
PCV139 EVALUATION OF A HEALTH CARE PROVIDER INTERVENTION TO INITIATE ACEI OR ARB THERAPY AMONG PATIENTS WITH DIABETES PLUS HYPERTENSION AND/OR NEPHROPATHY
Erickson SC, Gong S, Ebright KB, Stockl K, Shin JS, Lew HC, Harada A, Solow BK, Curtis B Prescription Solutions, Irvine, CA, USA OBJECTIVES: ACEI or ARB therapy in patients with diabetes has been shown to delay progression to renal failure. This study evaluated the impact of a mailing intervention to health care providers aimed at optimizing ACEI or ARB therapy in patients with diabetes plus hypertension and/or nephropathy. METHODS: A retrospective cohort study was performed using pharmacy claims data from a large Medicare Part D plan to evaluate an intervention notifying providers of missing ACEI/ARB therapy for 28,348 patients with diabetes plus hypertension and/or nephropathy not qualifying for Medication Therapy Management services (Non-MTM). A control cohort of 50,757 Non-MTM Medicare Part D patients with diabetes plus hypertension and/or nephropathy not receiving ACEI or ARB therapy during the 7-month identification period was selected from an earlier timeframe to be compared to the intervention cohort. The primary outcome was the percentage of identified patients initiating ACEI or ARB therapy during the 4-month post-intervention period. Logistic regression was performed using a dependent variable of initiation vs. no initiation of ACEI or ARB therapy in the post-intervention period. Independent variables included age, gender, chronic disease score, and hypertension and nephropathy diagnoses. RESULTS: During the post-intervention period, the unadjusted proportion of those beginning ACEI or ARB therapy was 15.0% for the intervention group compared to 12.2% for the control group (p < 0.0001). After adjusting for baseline characteristics, intervened patients had greater odds of initiating ACEI or ARB therapy compared to control patients (OR 1.40; 95% CI 1.33-1.48). A limitation of the evaluation is that the identification and measurement periods for the control group were in a different part of the year than the intervention cohort. CONCLUSIONS: Intervention in patients with diabetes plus hypertension and/or nephropathy via health care providers demonstrated an increased likelihood of initiation of ACEI or ARB therapy compared to a control group.
PCV140 UNDERSTANDING THE CURRENT LIPID PROFILE, TREATMENT, AND CASE MIX OF PATIENTS WITH DYSLIPIDEMIA IN A REAL-WORLD POPULATION
Fox KM 1 , Bullano MF 2 , Shoetan N 2 , Gandhi SK 2 1 Strategic Healthcare Solutions, LLC, Monkton, MD, USA, 2 AstraZeneca LP, Wilmington, DE, USA OBJECTIVES: In addition to elevated low-density lipoprotein cholesterol (LDL-C), studies have implicated decreased high-density lipoprotein cholesterol (HDL-C) and elevated triglycerides (TG) as independent modifiable risk factors for cardiovascular disease. This study determined the proportion of patients with a single lipid abnormality (SLA) versus mixed dyslipidemia and their respective treatments among a large sample of managed care patients. METHODS: A retrospective cohort study of adults with a complete lipid panel between 1/1/2005 and 12/31/2008 in a US national health plan with >10 million commercial and Medicare Advantage members was conducted. SLA was defined as one of the following: high LDL-C based on NCEP ATP III guidelines, low HDL-C (<40 mg/dL), or high TG (≥200 mg/dL). Mixed dyslipidemia was defined as having ≥2 of the lipid abnormalities. Proportion of patients with an SLA or mixed dyslipidemia and lipid-modifying therapy patterns were evaluated. RESULTS: A total of 247,322 patients had dyslipidemia in the 4-year observation period; 68% had an SLA and 32% had mixed dyslipidemia. Of patients with SLA, 47% had elevated LDL-C, 32% had low HDL-C, and 21% had elevated TG. For patients with an SLA, only 29% received lipid-modifying therapy, with 71% of those receiving statin monotherapy. Of patients with mixed dyslipidemia, 42% had low HDL-C and high TG, 22% had high LDL-C and low HDL-C, 21% had high LDL-C and high TG, and 15% had all 3 abnormal lipid parameters. In the mixed dyslipidemia group, only 33% received lipid-modifying therapy, with 58% of those receiving statin monotherapy and 19% receiving multi-pill combination therapy. CONCLUSIONS: The lack of treatment and inadequate treatment observed in this real-world study indicates an unmet medical need in managing lipid levels among dyslipidemic patients, including patients with mixed dyslipidemia.
PCV141 UTILIZATIONAND EXPENDITURE TRENDS FOR BOTH ANGIOTENSIN-CONVERTING ENZYME INHIBITORS AND ANGIOTENSIN RECEPTOR BLOCKERS IN THE MEDICAID PROGRAM
Bian B 1 , Guo JJ 2 , Kelton C 2 , Wigle P 1 1 Univeristy of Cincinnati, Cincinnati, OH, USA, 2 University of Cincinnati, Cincinnati, OH, USA OBJECTIVES: Both angiotensin-converting-enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) have been widely used for treatment of hypertension, heart failure, diabetes mellitus and kidney disease. The purposes of this study were to describe the utilization, price and expenditure trends of ACEIs and ARBs and to assess market-share competition between ACEIs and ARBs. METHODS: A retrospective, descriptive time-series analysis was performed using the National Medicaid pharmacy claims database from 1991 to 2008. The quarterly prescription numbers and reimbursement amounts were calculated over time by summing data for individual drug products. The quarterly per-prescription reimbursement as a proxy for drug price was computed for all brands and generics of ACEIs and ARBs. The market shares were calculated based on both prescription numbers and Medicaid payments. RESULTS: The ACEI prescriptions increased from 4.8 million in 1991 to 16.5 million in 2004, then dropped to 2.3 million in 2008. Meanwhile, ARB prescriptions increased from 0.03 million in 1995 to 7.5 million in 2004, then dropped to 2.1 million in 2008. Concurrently, annual expenditure for ACEIs increased from $179 million in 1991 to $593 million in 2002, and dropped to $64 million in 2008. Expenditure for ARBs increased from $1.3 million in 1995 to $515 million in 2005, and dropped to $174 million in 2008. Market shares for generic ACEIs like captopril, lisinopril and enalapril increased rapidly. All brand-name prices for ARBs and ACEIs increased over time regardless of new branded or generic drug entry, while generic prices decreased over time. CONCLUSIONS: Dramatically increased utilization of both ACEIs and ARBs may be due to their wide therapeutic indications and efficacy. A significant drop in utilization from 2006-2008 was related to the introduction of Medicare Part D. Increased utilization of generic ACEIs was likely due to the Medicaid generic substitution policy and changes in prescribing patterns.
